The content of this evidence summary was up-to-date in October 2020. See summaries of product characteristics (SPCs), British national formulary (BNF) or the Medicines and Healthcare products Regulatory Agency (MHRA) or NICE websites for up-to-date information.
Imipenem with cilastatin and relebactam (Recarbrio, Merck Sharp & Dohme B.V) is given intravenously and is a combination of a broad-spectrum carbapenem antibiotic (imipenem); an inhibitor of dehydropeptidase-I, the renal enzyme that metabolises and inactivates imipenem (cilastatin); and a beta-lactamase inhibitor (relebactam). Only imipenem has antibacterial activity. Imipenem with cilastatin and relebactam has a marketing authorisation for treating infections caused by aerobic gram-negative organisms in adults with limited treatment options.